The Food Drug and Administration recently approved a drug that may help patients in the early stages of Alzheimer's by slowing down the progression of the disease. In clinical trials, the drug called lecanemab reduced the rate of cognitive decline among participants.
the drug to Alzheimer's patients. Due to the controversy surrounding the drug's efficacy and its high price, as well as the negative publicity it has received, few patients have gotten the treatment. As a result, many doctors who treat the disease have been left, once again, with limited options.
Like Aduhelm, the drug lecanemab was developed by Eisai in partnership with fellow drugmaker Biogen. These treatments are monoclonal antibody therapies that are designed to remove a substance called beta-amyloid from the brain. Beta-amyloid is a naturally occurring protein that becomes toxic when it clumps together and forms the sticky plaques that are a hallmark of Alzheimer’s disease.
“The clinical trial data shows a statistically significant but clinically undetectable difference in the outcome measure between active treatment and placebo over 18 months,” Dr. Michael Greicius, a professor of neurology and neurological sciences at Stanford University, told Yahoo News. “I do consider it a game changer but in a negative sense for how it will change the clinical and research landscape around Alzheimer’s disease,” Greicius said.
If CMS ultimately decides not to cover lecanemab, Greicius said, the drug will likely be used but not very widely, as it would have to be paid for out of pocket.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Senior FDA official resigns in wake of 2022 infant formula shortage, acknowledges FDA communication breakdownsFDA's Deputy Commissioner for Food Policy and Response, Frank Yiannas, has announced he is resigning from his post. His departure comes in the wake of last year's infant formula shortage, throughout which Yiannas held a prominent leadership role.
Lire la suite »
Anand Kumar: We shouldn’t get caught up in the hype over new Alzheimer’s drugAnand Kumar writes: “We are ill-served by overinterpreting statistical significance, heralding the false dawn and expediting the approval of ineffective, inadequately tested drugs under the umbrella of “cutting-edge science.
Lire la suite »
FDA panel endorses changing primary COVID vaccinesAn FDA expert panel on Thursday unanimously recommended that the U.S. overhaul its pandemic vaccine strategy and replace initial doses of original COVID shots with bivalent ones that target specific Omicron subvariants.
Lire la suite »
Alzheimer’s study in Boston looking at possible treatment to prevent the diseaseBoston medical researchers are hoping to get ahead of Alzheimer’s by testing a possible treatment in patients who don’t have symptoms but may be at risk for the progressive disease.
Lire la suite »
Update: Circle (Gaon) Chart Music Awards Announces 2nd Lineup Of ArtistsUpdate: Circle (Gaon) Chart Music Awards Announces 2nd Lineup Of Artists
Lire la suite »
EU regulator accepts for review Alzheimer's treatment from Eisai-BiogenJapanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.
Lire la suite »